{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:26:49Z","timestamp":1782818809405,"version":"3.54.5"},"reference-count":64,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ando.2012.06.002","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T16:01:31Z","timestamp":1365264091000},"page":"515-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?"],"prefix":"10.1016","volume":"74","author":[{"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2012.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0140-6736(11)60207-9","article-title":"Management of type 2 diabetes: new and future developments in treatment","volume":"378","author":"Tahrani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00125-012-2561-x","article-title":"The incretin hormones: from scientific discovery to practical therapeutics","volume":"55","author":"Mudaliar","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.06.002_bib0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.06.002_bib0025","first-page":"1884","article-title":"Les incr\u00e9tinomim\u00e9tiques et incr\u00e9tinopotentiateurs dans le traitement du diab\u00e8te de type 2","volume":"3","author":"Scheen","year":"2007","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.ando.2012.06.002_bib0030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejim.2011.10.007","article-title":"Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes","volume":"23","author":"Scheen","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ando.2012.06.002_bib0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejim.2011.11.003","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no","volume":"23","author":"Madsbad","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ando.2012.06.002_bib0040","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4065\/mcp.2010.0469","article-title":"Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors","volume":"85","author":"Davidson","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ando.2012.06.002_bib0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-642-17214-4_3","article-title":"GLP-1 agonists and dipeptidyl peptidase IV inhibitors","volume":"203","author":"Gallwitz","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ando.2012.06.002_bib0050","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-642-24716-3_8","article-title":"Anorexigenic effects of GLP-1 and its analogues","volume":"209","author":"Gallwitz","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ando.2012.06.002_bib0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2012.06.002_bib0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.diabet.2012.04.003","article-title":"Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes","volume":"38","author":"Cariou","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0070","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2165\/11592810-000000000-00000","article-title":"Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents","volume":"71","author":"Gallwitz","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ando.2012.06.002_bib0075","first-page":"CD006423","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ando.2012.06.002_bib0080","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2012.06.002_bib0085","first-page":"158","article-title":"Ex\u00e9natide (Byetta\u00ae). Incr\u00e9tinomim\u00e9tique indiqu\u00e9 dans le traitement du diab\u00e8te de type 2 apres \u00e9chec et en compl\u00e9ment des antidiab\u00e9tiques oraux","volume":"63","author":"Scheen","year":"2008","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.ando.2012.06.002_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J3G883","article-title":"The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Nikfar","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.ando.2012.06.002_bib0095","first-page":"464","article-title":"Liraglutide (Victoza\u00ae)\u00a0: analogue du glucagon-like-peptide-1\u00a0humain en une injection par jour pour le traitement du diab\u00e8te de type 2","volume":"65","author":"Scheen","year":"2010","journal-title":"Rev Med Liege"},{"key":"10.1016\/j.ando.2012.06.002_bib0100","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2165\/11208110-000000000-00000","article-title":"Liraglutide: a review of its use in the management of type 2 diabetes mellitus","volume":"71","author":"Perry","year":"2011","journal-title":"Drugs"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.ando.2012.06.002_bib0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1463-1326.2012.01575.x","article-title":"Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents","volume":"14","author":"Blonde","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543784.2011.562191","article-title":"Lixisenatide for type 2 diabetes mellitus","volume":"20","author":"Christensen","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ando.2012.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(08)61207-6","article-title":"Exenatide once weekly in type 2 diabetes","volume":"372","author":"Scheen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0120","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1345\/aph.1Q722","article-title":"Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus","volume":"46","author":"Murphy","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ando.2012.06.002_bib0125","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1345\/aph.1Q024","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"45","author":"Pinelli","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ando.2012.06.002_bib0130","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1463-1326.2011.01523.x","article-title":"The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide","volume":"14","author":"Barnett","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0135","doi-asserted-by":"crossref","first-page":"672658","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like Peptide-1 receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.ando.2012.06.002_bib0140","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"Vilsboll","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2012.06.002_bib0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.diabet.2011.07.001","article-title":"Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system","volume":"37","author":"Verges","year":"2011","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0150","doi-asserted-by":"crossref","first-page":"215764","DOI":"10.1155\/2011\/215764","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials","volume":"2011","author":"Monami","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.ando.2012.06.002_bib0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ando.2012.06.002_bib0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1463-1326.2011.01376.x","article-title":"A cohort study of acute pancreatitis in relation to exenatide use","volume":"13","author":"Dore","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0165","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-0599","article-title":"The safety of incretin-based therapies: review of the scientific evidence","volume":"96","author":"Drucker","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0170","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/dmrr.1202","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review","volume":"27","author":"Aroda","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ando.2012.06.002_bib0175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1345\/aph.1Q583","article-title":"Drug-drug interactions with glucagon-like peptide-1 receptor agonists","volume":"46","author":"Hurren","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ando.2012.06.002_bib0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14656566.2012.642866","article-title":"A review of gliptins in 2011","volume":"13","author":"Scheen","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ando.2012.06.002_bib0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: systematic review and meta-analysis","volume":"29","author":"Monami","year":"2012","journal-title":"Adv Ther"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.ando.2012.06.002_bib0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1185\/03007995.2011.602964","article-title":"Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials","volume":"27","author":"Monami","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ando.2012.06.002_bib0195","article-title":"Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis","author":"Goossen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0200","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","article-title":"Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials","volume":"34","author":"Monami","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2012.06.002_bib0205","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","article-title":"Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase","volume":"34","author":"Willemen","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2012.06.002_bib0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3810\/pgm.2011.11.2508","article-title":"The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors","volume":"123","author":"Morales","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ando.2012.06.002_bib0215","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2010.02382.x","article-title":"Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis","volume":"64","author":"Engel","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ando.2012.06.002_bib0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/11532980-000000000-00000","article-title":"Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions","volume":"49","author":"Scheen","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ando.2012.06.002_bib0225","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0230","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1517\/17425255.2011.628986","article-title":"Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)","volume":"7","author":"Scheen","year":"2011","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ando.2012.06.002_bib0235","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0140-6736(10)60399-6","article-title":"Addition of incretin therapy to metformin in type 2 diabetes","volume":"375","author":"Scheen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0240","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes: a review and meta-analysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0245","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review","volume":"34","author":"Aroda","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ando.2012.06.002_bib0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2012.06.002_bib0255","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ando.2012.06.002_bib0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0265","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","article-title":"DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once weekly exenatide","volume":"28","author":"Wysham","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.ando.2012.06.002_bib0270","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2012.06.002_bib0275","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2012.06.002_bib0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","article-title":"One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial","volume":"65","author":"Pratley","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ando.2012.06.002_bib0285","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","article-title":"Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"52","author":"Nathan","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.06.002_bib0290","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","article-title":"Is the ADA\/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis","volume":"53","author":"Schernthaner","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.06.002_bib0295","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ando.2012.06.002_bib0300","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.06.002_bib0305","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1007\/s00125-012-2635-9","article-title":"Controversy about the relative efficacy of DPP-4 inhibitors","volume":"55","author":"Scheen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.06.002_bib0310","unstructured":"International Diabetes Federation. Treatment algorithm for people with type 2 diabetes. http:\/\/wwwidforg\/treatment-algorithm-people-type-2-diabetes?language=fr. 2012."},{"key":"10.1016\/j.ando.2012.06.002_bib0315","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s12325-012-0008-x","article-title":"Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?","volume":"29","author":"Paolisso","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.ando.2012.06.002_bib0320","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1530\/EJE-07-0804","article-title":"Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?","volume":"158","author":"Van Gaal","year":"2008","journal-title":"Eur J Endocrinol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426613000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426613000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:46:30Z","timestamp":1757717190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426613000188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":64,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0003426613000188"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2012.06.002","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2012.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}